SCHEMBL5579042

SCHEMBL5579042

CC(C)(C)C(=O)CNC(=O)C1(N(C(=O)O)C(C)(C)C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15796098 0.82 OPRM1 (0.32)
SCHEMBL15795366 0.78 SMN1; SMN2 (0.32)
SCHEMBL15795898 0.78
SCHEMBL15795970 0.77
SCHEMBL15795096 0.76 P2RX7 (0.31)
SCHEMBL17501715 0.72
SCHEMBL4702292 0.69 CTSL (0.32)
SCHEMBL14910753 0.69
SCHEMBL1645775 0.65 CYP2D6 (0.39)
SCHEMBL22733964 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149525-A1 Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors ELAN PHARMACEUTICALS, INC. 2007-06-28 US disclosed